Mizagliflozin
AssetAlso called VGX-001-013, EMERGE, DSP-3235, KGA-3235
Inhibits intestinal SGLT1 to reduce glucose absorption and blunt postprandial glucose excursions.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 2
- Trials
- 1
- Developer
Trial NCT07760961 is still running. Mizagliflozin: data expected on Nov 6, 2026. SEC filing
Indications
1Postbariatric hypoglycemia
Phase 2, Completed, NCT05721729, clinicaltrials.gov, Nov 17, 2026
In the full profile
- Owner and partners1
- Trials2
- Evidence for its targets1
- Signals4
Every asset’s record: target, stage, trials and the evidence behind it.